Severe pulmonary hypertensive diseases: A perspective

European Respiratory Journal

Volumn 14, Issue 6, 1999, Pages 1246-1250

  Voelkel, N F ^a   Tuder, R M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Plexiform arteriopathy; Primary pulmonary hypertension; Prostacyclin; Pulmonary hypertension classification; Vasodilator treatment; Veno occlusive disease

Indexed keywords

CELL PROLIFERATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VEIN OCCLUSION;

EID: 0033398310     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.99.14612469     Document Type: Review

References (27)

1. Heath D, Edwards JE. The pathology of pulmonary hypertensive disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal changes. Circulation 1958; 18: 533.
2. Primary Pulmonary Hypertension: report on a WHO Meeting. Hatano S, Strasser T, eds. Geneva; World Health Organization, 1975.
3. Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular disease. Chest 1980; 77: 614-625.
4. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-141.
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
6. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 1987; 57: 270-278.
7. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
8. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
9. Mark EJ, Patalas ED, Change HT, Evans RJ, Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997; 337: 602-605.
10. Tuder RM, Radisavljevic Z, Shroyer KR, Polak JM, Voelkel NF. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 1998; 158: 1999-2001.
11. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Sitbon O, Simonneau O. Treatment of severe pulmonary hypertension secondary to connective tissue disease with continuous IV epoprostenol (prostacyclin). Chest 1998; 114:80S-82S.
12. Kuo PC, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604-606.
13. Wagenvoort CA, Wagenvoort N. Pathology of Pulmonary Hypertension. New York, John Wiley and Sons, 1977.
14. Gimbrone MAJ, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 1997; 100: S61-S65.
15. Cool CD, Steward JC, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Path 1999; 155: 411-419.
16. Nichols WC, Killer DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15: 277-280.
17. Morse JH, Jones AC, Barst RJ, et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997; 95: 2603-2606.
18. Lee SD, Shroyer Kr, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101: 927-934.
19. Cool CD, Tuder RM, Voelkel NF. Plexiform pulmonary vascular lesions in scleroderma and AIDS: is there a common pathogenesis? Hum Pathol 1997; 28: 434-442.
20. Cool CD, Voelkel NF, Wheeler LJ, Tuder RM. Analysis of vascular lesions in familial primary pulmonary hypertension (FPPH): insights into the endothelial cell as the common denominator of a morphologically heterogeneous disorder. Am J Resp Crit Care Med 1997; 155: A628.
21. Tuder RM, Cool CD, Jennings C, Voelkel NF. Pulmonary vascular involvement in interstitial lung disease. In: Schwartz SM, King TEJ, eds. Interstitial Lung Disease. 3rd Edn. Hamilton, Ontario, Canada, BC Decker, 1998; pp. 251-263.
22. Tuder RM, Groves GM, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285.
23. Groves BM, Badesch DB, Turkevich D, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir EK, Hume JR, Reeves JT, eds. Ion Flux in Pulmonary Vascular Control. New York, Plenum Publishing, 1993; pp. 317-330.
24. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term testing with prostacyclin in primary pulmonary hypertension. Circulation 1996; 93: 484-488.
25. Mclaughlin V.V., Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with longterm epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
26. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991; 338: 1173-1174.
27. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270.